Murdoch Childrens Research Institute, Royal Children's Hospital and University of Melbourne, Parkville, Victoria, Australia.
Fertil Steril. 2012 Oct;98(4):836-42. doi: 10.1016/j.fertnstert.2012.06.022. Epub 2012 Jul 3.
To assess the effect on spermatogenesis of adding recombinant follicle-stimulating hormone (FSH) to human chorionic gonadotropin (hCG) treatment protocols for adolescent/young adult males with hypogonadotropic hypogonadism (HH).
Observational descriptive study.
Outpatient clinics.
PATIENT(S): Nineteen males with hypogonadotropic hypogonadism, aged 14.5 to 31.0 years.
INTERVENTION(S): Treatment with either hCG treatment alone (n = 9; group 1) or in combination with recombinant FSH (n = 10; group 2), over 6 to 9 months.
MAIN OUTCOME MEASURE(S): Combined testicular volume (CTV) and testosterone, inhibin B, semen/urine analysis at 6 to 9 months.
RESULT(S): There were no differences between the two groups in baseline variables or changes in CTV with treatment. Despite this, evidence of spermatogenesis was present in all group 2 patients by 9 months (range 0.2 to 15 × 10(6)/mL) compared with three of nine patients in group 1 (range 0 to <1 × 10(6)/mL). Whole group and subgroup analyses did not demonstrate any statistically significant correlations between age at onset of treatment and either CTV or sperm count.
CONCLUSION(S): The addition of recombinant FSH to hCG treatment protocols in adolescent/young adult HH males results in normal testicular growth and may hasten induction of spermatogenesis.
评估在人绒毛膜促性腺激素（hCG）治疗方案中添加重组卵泡刺激素（FSH）对青春期/年轻男性低促性腺激素性性腺功能减退症（HH）患者的生精作用。
观察性描述性研究。
门诊诊所。
19 名低促性腺激素性性腺功能减退症男性，年龄 14.5 至 31.0 岁。
单独使用 hCG 治疗（n = 9；第 1 组）或与重组 FSH 联合治疗（n = 10；第 2 组），治疗时间为 6 至 9 个月。
6 至 9 个月时的联合睾丸体积（CTV）和睾酮、抑制素 B、精液/尿液分析。
两组患者的基线变量或治疗期间 CTV 的变化均无差异。尽管如此，第 2 组所有患者在 9 个月时均出现生精迹象（范围 0.2 至 15×10(6)/mL），而第 1 组 9 名患者中仅有 3 名（范围 0 至 <1×10(6)/mL）。全组和亚组分析均未显示治疗起始年龄与 CTV 或精子计数之间存在任何统计学显著相关性。
在青春期/年轻男性 HH 患者的 hCG 治疗方案中添加重组 FSH 可导致正常睾丸生长，并可能加速生精作用。
